{'fraction_non_alphanumeric': 0.04229848363926576, 'fraction_numerical': 0.03750997605746209, 'mean_word_length': 4.225, 'pattern_counts': {'":': 0, '<': 1, '<?xml version=': 0, '>': 1, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Russian Open Medical Journal

Introduction — Secondary hyperparathyroidism (SHPT) is common in patients with chronic kidney disease (CKD) affecting most of the patients in end stage renal disease. Materials and Methods — This prospective case control study was conducted on 50 adult patients of CKD, having  individual parathyroid hormone  (iPTH)  levels >300 pg/ml. These patients were divided  into  two groups: Group  I  (n=25) received calcitriol in dosage of 0.5 μg/day. Group II (n=25) received cinacalcet in dosage of 30 mg/day and calcitriol 0.5 μg/day. The study was carried out for 6 month duration.  Results — The mean basal value of iPTH decreased to 246.40±219.99 pg/ml at the end of the study from basal value of 482.80±229.86 in group II. There was a 43% decrease in serum iPTH values in group II as opposed to the 14% decrease in group I (P<0.05). Serum Ca×P decreased by 9% in group I and by 13% in group II and there was statistically significant difference at the end of 3 month as well as at the end of study in cinacalcet group. Conclusion — Cinacalcet is unique in its ability to simultaneously lower PTH, calcium, phosphorus and Ca×P in patients with SHPT and thus could become an important component in treatment of CKD patients.